122 related articles for article (PubMed ID: 27376840)
1. Alendronate- and risedronate-induced acute polyarthritis.
Uğurlar M
Osteoporos Int; 2016 Nov; 27(11):3383-3385. PubMed ID: 27376840
[TBL] [Abstract][Full Text] [Related]
2. Response to oral bisphosphonates in subgroups of younger and older postmenopausal women.
Stovall DW; Beard MK; Barbier S; Chen E; Rosenberg E; de Papp AE
J Womens Health (Larchmt); 2010 Mar; 19(3):491-7. PubMed ID: 20141367
[TBL] [Abstract][Full Text] [Related]
3. [Persistent polyarticular synovitis after treatment with alendronate].
Frederiksen L; Junker P; Brixen KT
Ugeskr Laeger; 2007 Apr; 169(17):1583-4. PubMed ID: 17484832
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
5. Safety considerations with bisphosphonates for the treatment of osteoporosis.
Strampel W; Emkey R; Civitelli R
Drug Saf; 2007; 30(9):755-63. PubMed ID: 17722968
[TBL] [Abstract][Full Text] [Related]
6. Possible alendronate-induced polyarticular synovitis.
Gökkus K; Yazicioglu G; Sagtas E; Uyan A; Aydin AT
J Postgrad Med; 2016; 62(2):126-8. PubMed ID: 26767974
[TBL] [Abstract][Full Text] [Related]
7. Bone Mass Outcomes in Patients With Osteoporosis Treated With Risedronate After Alendronate Failure: a 12-Month Follow-Up Study.
Mendonça LT; Pinheiro MM; Szejnfeld VL; Castro CH
J Clin Densitom; 2017; 20(1):44-49. PubMed ID: 27616291
[TBL] [Abstract][Full Text] [Related]
8. Changes in bone resorption markers among Japanese patients with postmenopausal osteoporosis treated with alendronate and risedronate.
Takada J; Iba K; Imoto K; Yamashita T
J Bone Miner Metab; 2007; 25(2):142-6. PubMed ID: 17323185
[TBL] [Abstract][Full Text] [Related]
9. Alendronate-induced synovitis.
Gwynne Jones DP; Savage RL; Highton J
J Rheumatol; 2008 Mar; 35(3):537-8. PubMed ID: 18203307
[TBL] [Abstract][Full Text] [Related]
10. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
11. The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women.
Yanik B; Bavbek N; Yanik T; Inegöl I; Kanbay M; Turgut FH; Uz E; Akçay A
Ren Fail; 2007; 29(4):471-6. PubMed ID: 17497471
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
Sarioglu M; Tuzun C; Unlu Z; Tikiz C; Taneli F; Uyanik BS
Rheumatol Int; 2006 Jan; 26(3):195-200. PubMed ID: 15580349
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of osteoporosis by risedronate-- speed, efficacy and safety].
Giljević Z; Vlak T
Reumatizam; 2006; 53(2):66-71. PubMed ID: 17580558
[TBL] [Abstract][Full Text] [Related]
14. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
[TBL] [Abstract][Full Text] [Related]
15. Risedronate-induced arthritis.
Yemisci OU; Yalbuzdag SA; Karatas M
J Clin Rheumatol; 2010 Jun; 16(4):168-9. PubMed ID: 20414126
[TBL] [Abstract][Full Text] [Related]
16. Risk of upper gastrointestinal tract events in risedronate users switched to alendronate.
Ralston SH; Kou TD; Wick-Urban B; Steinbuch M; Masud T
Calcif Tissue Int; 2010 Oct; 87(4):298-304. PubMed ID: 20803291
[TBL] [Abstract][Full Text] [Related]
17. Oral bisphosphonate adverse effects in 849 patients with metabolic bone diseases.
Anastasilakis AD; Goulis DG; Kita M; Avramidis A
Hormones (Athens); 2007; 6(3):233-41. PubMed ID: 17724008
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
Bilezikian JP
Am J Med; 2009 Feb; 122(2 Suppl):S14-21. PubMed ID: 19187808
[TBL] [Abstract][Full Text] [Related]
19. Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review.
Kherani RB; Papaioannou A; Adachi JD
Drug Saf; 2002; 25(11):781-90. PubMed ID: 12222989
[TBL] [Abstract][Full Text] [Related]
20. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
Rosen CJ; Hochberg MC; Bonnick SL; McClung M; Miller P; Broy S; Kagan R; Chen E; Petruschke RA; Thompson DE; de Papp AE;
J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
